Nuvectis Pharma, Inc.
NVCTNASDAQHealthcare● Active
$9.42
$-0.12(-1.26%)
Market Cap$249870521
P/E Ratio—
52W High$13.34
52W Low$5.55
Nuvectis Pharma, Inc. (NVCT) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
NVCT · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 5, 2026EPS Actual
-$0.26
Est. -$0.30 · +13.3%
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 5, 2026
After Market Close
▲ Beat EPS✓ 1-Quarter EPS Beat Streak
NVCT reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$-0.06
Rev. $1.94B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$-0.06
Rev. Est.$1.94B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 4, 2026 | -$0.25 | — | — | — | — | — |
| ▲ Q2 FY2026 | May 5, 2026 | -$0.30 | -$0.26 | +13.3% | — | — | — |
| ▼ Q1 FY2026 | Feb 11, 2026 | -$0.26 | -$0.31 | -19.2% | — | — | — |
| ▼ Q4 FY2025 | Nov 4, 2025 | -$0.24 | -$0.44 | -83.3% | — | — | — |
| ▼ Q3 FY2025 | Aug 5, 2025 | -$0.25 | -$0.30 | -20.0% | — | — | — |
| ▲ Q2 FY2025 | May 6, 2025 | -$0.30 | -$0.27 | +10.0% | — | — | — |
| ▼ Q1 FY2025 | Feb 25, 2025 | -$0.28 | -$0.36 | -28.6% | — | — | — |
| ▲ Q4 FY2024 | Nov 5, 2024 | -$0.26 | -$0.24 | +7.7% | — | — | — |
Q3 FY2026
Aug 4, 2026
EPS Actual
—
EPS Est.
-$0.25
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 5, 2026Beat
EPS Actual
-$0.26
EPS Est.
-$0.30
EPS Surpr.
+13.3%
Revenue
—
Q1 FY2026
Feb 11, 2026Miss
EPS Actual
-$0.31
EPS Est.
-$0.26
EPS Surpr.
-19.2%
Revenue
—
Q4 FY2025
Nov 4, 2025Miss
EPS Actual
-$0.44
EPS Est.
-$0.24
EPS Surpr.
-83.3%
Revenue
—
Q3 FY2025
Aug 5, 2025Miss
EPS Actual
-$0.30
EPS Est.
-$0.25
EPS Surpr.
-20.0%
Revenue
—
Q2 FY2025
May 6, 2025Beat
EPS Actual
-$0.27
EPS Est.
-$0.30
EPS Surpr.
+10.0%
Revenue
—
Q1 FY2025
Feb 25, 2025Miss
EPS Actual
-$0.36
EPS Est.
-$0.28
EPS Surpr.
-28.6%
Revenue
—
Q4 FY2024
Nov 5, 2024Beat
EPS Actual
-$0.24
EPS Est.
-$0.26
EPS Surpr.
+7.7%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $-0.26 | $-0.26 | $-0.26 | 1 |
| Q3 FY2026 | $-0.28 | $-0.27 | $-0.26 | 3 |
| Q2 FY2026 | $-0.26 | $-0.26 | $-0.25 | 3 |
| Q1 FY2026 | $-0.31 | $-0.31 | $-0.30 | 3 |
| Q4 FY2025 | $-0.38 | $-0.32 | $-0.24 | 3 |
| Q3 FY2025 | $-0.27 | $-0.25 | $-0.22 | 4 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2025 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2025 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 5, 2026 | +13.3% | $8.89 | $9.71 | +9.22% |
| ▼ Q1 FY2026 | Feb 11, 2026 | -19.2% | $8.74 | $8.78 | +0.46% |
| ▼ Q4 FY2025 | Nov 4, 2025 | -83.3% | $6.36 | $5.88 | -7.55% |
| ▼ Q3 FY2025 | Aug 5, 2025 | -20.0% | $7.29 | $6.90 | -5.35% |
| ▲ Q2 FY2025 | May 6, 2025 | +10.0% | $9.37 | $8.96 | -4.38% |
| ▼ Q1 FY2025 | Feb 25, 2025 | -28.6% | $7.36 | $6.93 | -5.84% |
| ▲ Q4 FY2024 | Nov 5, 2024 | +7.7% | $6.31 | $7.43 | +17.75% |
| ▲ Q3 FY2024 | Aug 6, 2024 | +0.0% | $7.03 | $6.62 | -5.83% |
Q2 FY2026+9.22%
Report Date
May 5, 2026
EPS Beat/Miss
+13.3%
Price Before
$8.89
Price After
$9.71
Q1 FY2026+0.46%
Report Date
Feb 11, 2026
EPS Beat/Miss
-19.2%
Price Before
$8.74
Price After
$8.78
Q4 FY2025-7.55%
Report Date
Nov 4, 2025
EPS Beat/Miss
-83.3%
Price Before
$6.36
Price After
$5.88
Q3 FY2025-5.35%
Report Date
Aug 5, 2025
EPS Beat/Miss
-20.0%
Price Before
$7.29
Price After
$6.90
Q2 FY2025-4.38%
Report Date
May 6, 2025
EPS Beat/Miss
+10.0%
Price Before
$9.37
Price After
$8.96
Q1 FY2025-5.84%
Report Date
Feb 25, 2025
EPS Beat/Miss
-28.6%
Price Before
$7.36
Price After
$6.93
Q4 FY2024+17.75%
Report Date
Nov 5, 2024
EPS Beat/Miss
+7.7%
Price Before
$6.31
Price After
$7.43
Q3 FY2024-5.83%
Report Date
Aug 6, 2024
EPS Beat/Miss
+0.0%
Price Before
$7.03
Price After
$6.62
Avg Beat Reaction+4.19%
Avg Miss Reaction-4.57%
Beat Rate4 / 8 quarters
Largest Move+17.75% (Q4 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: NVCT ends December
Nuvectis Pharma, Inc. (NVCT) most recently reported earnings on May 5, 2026 for Q2 FY2026, posting EPS of $-0.26 — beating the analyst consensus of $-0.30 by +13.3%. The next NVCT earnings date is expected around September 1, 2026.
Each quarter, investors track NVCT earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. NVCT revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
NVCT's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
NVCT earnings · 5 questionsNuvectis Pharma, Inc.'s next earnings report is expected around September 1, 2026. NVCT typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; NVCT historically reports after market close (AMC).
NVCT earnings datewhen is NVCT earningsNVCT next earnings datewhen does NVCT report earningsNVCT earnings calendar
▸ Source: FMP · Nuvectis Pharma, Inc. SEC filings · US GAAP · Nuvectis Pharma, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026